Literature DB >> 16985883

Adverse events associated with hormonal therapy for prostate cancer.

Ravi J Kumar, Al Barqawi, E David Crawford.   

Abstract

With expanding indications for androgen deprivation therapy for the treatment of prostate cancer, it is imperative that health care providers be cognizant of the possible adverse effects of therapy, as well as their prevention and treatment. Neurologic and psychiatric effects include depression and declines in cognitive function. Musculoskeletal effects of hormonal therapy include osteoporosis, decrease in muscle mass, and fatigue. Gynecomastia, weight gain, and erectile dysfunction are also seen, as are hematologic effects. Further research is needed to evaluate alternative forms of therapy, such as intermittent hormonal deprivation and antiandrogen monotherapy.

Entities:  

Year:  2005        PMID: 16985883      PMCID: PMC1477613     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  41 in total

1.  Fatigue in patients with prostate cancer receiving hormone therapy.

Authors:  P Stone; J Hardy; R Huddart; R A'Hern; M Richards
Journal:  Eur J Cancer       Date:  2000-06       Impact factor: 9.162

2.  Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone-releasing hormone agonist therapy.

Authors:  K Marumo; S Baba; M Murai
Journal:  Int J Urol       Date:  1999-01       Impact factor: 3.369

3.  Predictors of skeletal muscle mass in elderly men and women.

Authors:  R N Baumgartner; D L Waters; D Gallagher; J E Morley; P J Garry
Journal:  Mech Ageing Dev       Date:  1999-03-01       Impact factor: 5.432

4.  Combination treatment versus LHRH alone in advanced prostatic cancer.

Authors:  P Ferrari; G Castagnetti; G Ferrari; B Baisi; A Dotti
Journal:  Urol Int       Date:  1996       Impact factor: 2.089

5.  The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation.

Authors:  E S Orwoll; S K Oviatt; M R McClung; L J Deftos; G Sexton
Journal:  Ann Intern Med       Date:  1990-01-01       Impact factor: 25.391

6.  Depression during hormonal treatment of prostate cancer.

Authors:  D E Rosenblatt; A Mellow
Journal:  J Am Board Fam Pract       Date:  1995 Jul-Aug

7.  The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer.

Authors:  J C Smith; S Bennett; L M Evans; H G Kynaston; M Parmar; M D Mason; J R Cockcroft; M F Scanlon; J S Davies
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

8.  Gabapentin for hot flashes in prostate cancer.

Authors:  Sean M Jeffery; Jeffrey J Pepe; Lisa M Popovich; Gail Vitagliano
Journal:  Ann Pharmacother       Date:  2002-03       Impact factor: 3.154

9.  A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinoma of the prostate.

Authors:  J A Smith
Journal:  J Urol       Date:  1994-07       Impact factor: 7.450

10.  Megestrol acetate for the prevention of hot flashes.

Authors:  C L Loprinzi; J C Michalak; S K Quella; J R O'Fallon; A K Hatfield; R A Nelimark; A M Dose; T Fischer; C Johnson; N E Klatt
Journal:  N Engl J Med       Date:  1994-08-11       Impact factor: 91.245

View more
  31 in total

1.  The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2006

Review 2.  The role of physical rehabilitation in stem cell transplantation patients.

Authors:  Amir Steinberg; Arash Asher; Charlotte Bailey; Jack B Fu
Journal:  Support Care Cancer       Date:  2015-05-14       Impact factor: 3.603

3.  [Quality of life of patients with prostate cancer under androgen deprivation with GnRH analogues: Results of the noninterventional study TRIPTOSIX].

Authors:  A Eisenhardt; T Schneider; K Scheithe; C Colling; A Heidenreich
Journal:  Urologe A       Date:  2016-02       Impact factor: 0.639

Review 4.  Testosterone physiology in resistance exercise and training: the up-stream regulatory elements.

Authors:  Jakob L Vingren; William J Kraemer; Nicholas A Ratamess; Jeffrey M Anderson; Jeff S Volek; Carl M Maresh
Journal:  Sports Med       Date:  2010-12-01       Impact factor: 11.136

5.  Cognitive and neurobehavioral symptoms in patients with non-metastatic prostate cancer treated with androgen deprivation therapy or observation: A mixed methods study.

Authors:  Lisa M Wu; Molly L Tanenbaum; Marcel P J M Dijkers; Ali Amidi; Simon J Hall; Frank J Penedo; Michael A Diefenbach
Journal:  Soc Sci Med       Date:  2016-03-17       Impact factor: 4.634

Review 6.  Androgen deprivation therapy for prostate cancer: implications for cardiometabolic clinical care.

Authors:  L Collins; N Mohammed; T Ahmad; S Basaria
Journal:  J Endocrinol Invest       Date:  2012-02-28       Impact factor: 4.256

7.  Intermittent androgen deprivation therapy: redefining the standard of care?

Authors:  Neal D Shore; E David Crawford
Journal:  Rev Urol       Date:  2010

8.  Impact of age at diagnosis on prostate cancer treatment and survival.

Authors:  Seth K Bechis; Peter R Carroll; Matthew R Cooperberg
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

Review 9.  Evidence-based consensus recommendations to improve the quality of life in prostate cancer treatment.

Authors:  Francesc Casas; Josep María Borràs; Ferran Ferrer; Núria Guanyabens; Rafael Gutiérrez del Pozo; Concha León; José López Torrecilla; Begoña Mellado; Joan Morote; Manel Puig; María José Ribal; Carme Ruscalleda; Agustí Serra; Valentí Valls; Almudena Zapatero
Journal:  Clin Transl Oncol       Date:  2010-05       Impact factor: 3.405

10.  Development and validation of the korean version of expanded prostate cancer index composite: questionnaire assessing health-related quality of life after prostate cancer treatment.

Authors:  Kyung Jin Chung; Jung Jun Kim; Soo Hyun Lim; Tae Heon Kim; Deok Hyun Han; Sung Won Lee
Journal:  Korean J Urol       Date:  2010-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.